重新审视肠道微生物群在降脂他汀类药物莫纳可林 K（洛伐他汀）转化为其活性β-羟基酸代谢物中的作用。
Re-examining the role of the gut microbiota in the conversion of the lipid-lowering statin monacolin K (lovastatin) into its active β-hydroxy acid metabolite.
机构信息
Laboratory of Food & Health, Research Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, P.O. Box 164, 30100 Campus de Espinardo, Murcia, Spain.
出版信息
Food Funct. 2019 Apr 17;10(4):1787-1791. doi: 10.1039/c8fo02594k.
Monacolin K (MK, lovastatin), a naturally occurring statin, only exerts lipid-lowering effects in its active β-hydroxy acid form (MKA). This activation was thought to be mediated by the gut microbiota (GM). We report here for the first time that the GM does not convert MK into MKA (a spontaneous pH-dependent conversion) but catabolises MKA. The GM might hamper the lipid-lowering effects by degrading the active metabolite MKA.
洛伐他汀（MK，美伐他汀）是一种天然的他汀类药物，只有在其活性β-羟基酸形式（MKA）下才具有降脂作用。这种激活被认为是由肠道微生物群（GM）介导的。我们在这里首次报道 GM 不会将 MK 转化为 MKA（一种自发的 pH 依赖性转化），而是会将 MKA 代谢掉。GM 可能通过降解活性代谢物 MKA 来阻碍降脂作用。
Zotero 插件